Teclistamab, a bispecific antibody (BsAb) targeting CD3 on T cells and B-cell maturation antigen (BCMA) on myeloma cells, was approved in the United States (U.S.)in October 2022 for relapsed/refractory multiple myeloma (RRMM) for patients previously treated with four or more prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody. This evidence concerns the gene PPIB and plasma cell myeloma.